NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VR
Post# of 26
(Total Views: 206)
Posted On: 02/28/2018 4:44:02 PM
NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists further develop proprietary strains that can produce consistent and optimal therapeutic effects in patients. We want to put in place a collaborative agreement with BioCan, which will outline this development work and related intellectual property as well as the approach to profit-sharing,” Veritas Pharma CEO, Dr. Lui Franciosi stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing the genetics of the cannabis plants for scientific and clinical testing over the next two years is the company’s primary focus during the collaboration. Definitive agreements relating to the MOU are anticipated to be signed by July 31, 2018. “BioCan’s geneticists will help CTL scientists further develop proprietary strains that can produce consistent and optimal therapeutic effects in patients. We want to put in place a collaborative agreement with BioCan, which will outline this development work and related intellectual property as well as the approach to profit-sharing,” Veritas Pharma CEO, Dr. Lui Franciosi stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Indigenous Bloom Hemp Corp (VRTHF) Stock Research Links
Scroll down for more posts ▼